• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis.

作者信息

Innocenti Idanna, Morelli Francesca, Autore Francesco, Corbingi Andrea, Pasquale Raffaella, Sorà Federica, Pompili Maurizio, Laurenti Luca

机构信息

a Institute of Hematology , Università Cattolica del Sacro Cuore , Roma , Italy.

b Institute of Hematology , Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore , Roma , Italy.

出版信息

Leuk Lymphoma. 2019 May;60(5):1340-1342. doi: 10.1080/10428194.2018.1523401. Epub 2019 Feb 7.

DOI:10.1080/10428194.2018.1523401
PMID:30730231
Abstract
摘要

相似文献

1
HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis.在未进行病毒预防的情况下接受依鲁替尼治疗的隐匿性HBV感染的CLL患者中HBV再激活。
Leuk Lymphoma. 2019 May;60(5):1340-1342. doi: 10.1080/10428194.2018.1523401. Epub 2019 Feb 7.
2
Is HBV prophylaxis required during CLL treatment with ibrutinib?在使用依鲁替尼治疗慢性淋巴细胞白血病（CLL）期间是否需要进行乙肝病毒（HBV）预防？
Leuk Lymphoma. 2017 Dec;58(12):2966-2968. doi: 10.1080/10428194.2017.1317094. Epub 2017 May 23.
3
Feasibility and safety of therapy with ibrutinib after antiviral control of hepatitis B virus (HBV) reactivation in chronic lymphocytic leukemia patients.慢性淋巴细胞白血病患者乙肝病毒（HBV）再激活抗病毒控制后使用依鲁替尼治疗的可行性和安全性。
Leuk Lymphoma. 2018 Nov;59(11):2734-2736. doi: 10.1080/10428194.2018.1436175. Epub 2018 Feb 21.
4
What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Ibrutinib should be standard frontline therapy.老年慢性淋巴细胞白血病患者的标准一线治疗应该是什么？依鲁替尼应作为标准一线治疗。
Clin Adv Hematol Oncol. 2016 May;14(5):330-3.
5
Occult HBV reactivation induced by ibrutinib treatment: a case report.依鲁替尼治疗引起的隐匿性乙肝病毒再激活：一例报告
Acta Gastroenterol Belg. 2015 Dec;78(4):424-6.
6
Severe hepatitis B virus reactivation related to ibrutinib monotherapy.与伊布替尼单药治疗相关的严重乙型肝炎病毒再激活
Ann Hematol. 2017 Apr;96(4):689-690. doi: 10.1007/s00277-016-2917-2. Epub 2017 Jan 5.
7
Chronic lymphocytic leukemia, autoimmune hemolytic anemia and ibrutinib: a case report and review of the literature.慢性淋巴细胞白血病、自身免疫性溶血性贫血与伊布替尼：一例报告及文献综述
Leuk Lymphoma. 2016;57(3):735-7. doi: 10.3109/10428194.2015.1071489. Epub 2015 Oct 12.
8
Ibrutinib: searching for a partner drug.伊布替尼：寻找联合用药伙伴
Lancet Oncol. 2019 Jan;20(1):3-5. doi: 10.1016/S1470-2045(18)30861-1. Epub 2018 Dec 3.
9
What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Chemoimmunotherapy should be standard frontline therapy.老年慢性淋巴细胞白血病患者的标准一线治疗应该是什么？化学免疫疗法应作为标准一线治疗。
Clin Adv Hematol Oncol. 2016 May;14(5):336-8.
10
Invasive aspergillosis with pulmonary and central nervous system involvement during ibrutinib therapy for relapsed chronic lymphocytic leukaemia: case report.依鲁替尼治疗复发慢性淋巴细胞白血病期间并发累及肺和中枢神经系统的侵袭性曲霉病：病例报告
Clin Microbiol Infect. 2018 Jul;24(7):785-786. doi: 10.1016/j.cmi.2018.01.028. Epub 2018 Feb 7.

引用本文的文献

1
Drug-Induced Liver Injury Associated With Emerging Cancer Therapies.与新兴癌症治疗相关的药物性肝损伤
Liver Int. 2025 Feb;45(2):e70002. doi: 10.1111/liv.70002.
2
Management of infections for patient treated with ibrutinib in clinical practice.临床实践中接受依鲁替尼治疗患者的感染管理
Front Oncol. 2024 Sep 10;14:1428464. doi: 10.3389/fonc.2024.1428464. eCollection 2024.
3
Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents.慢性淋巴细胞白血病：靶向药物时代不良事件的管理
Cancers (Basel). 2024 May 24;16(11):1996. doi: 10.3390/cancers16111996.
4
Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era.靶向治疗时代血液系统恶性肿瘤患者乙型肝炎病毒再激活的预防与管理。
World J Gastroenterol. 2023 Sep 7;29(33):4942-4961. doi: 10.3748/wjg.v29.i33.4942.
5
Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy.接受布鲁顿酪氨酸激酶抑制剂治疗的复发或难治性弥漫性大 B 细胞淋巴瘤患者的乙型肝炎病毒再激活风险。
Front Immunol. 2022 Aug 31;13:982346. doi: 10.3389/fimmu.2022.982346. eCollection 2022.
6
B cell receptor signaling drives APOBEC3 expression via direct enhancer regulation in chronic lymphocytic leukemia B cells.B 细胞受体信号通过慢性淋巴细胞白血病 B 细胞中的直接增强子调控驱动 APOBEC3 的表达。
Blood Cancer J. 2022 Jul 1;12(7):99. doi: 10.1038/s41408-022-00690-w.
7
Managing the Risk of Infection in Chronic Lymphocytic Leukemia in the Era of New Therapies.管理新型疗法时代慢性淋巴细胞白血病的感染风险。
Curr Oncol Rep. 2022 Aug;24(8):1003-1014. doi: 10.1007/s11912-022-01261-9. Epub 2022 Apr 2.
8
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study.接受依鲁替尼治疗的慢性淋巴细胞白血病患者无论有无抗病毒预防措施时乙肝病毒再激活的风险。一项回顾性多中心GIMEMA研究。
Haematologica. 2022 Jun 1;107(6):1470-1473. doi: 10.3324/haematol.2021.280325.
9
Successful Control of Hepatitis B Virus Reactivation following Restart of Ibrutinib in Chronic Lymphocytic Leukaemia.慢性淋巴细胞白血病患者重新使用伊布替尼后成功控制乙肝病毒再激活
Case Rep Hematol. 2021 Oct 21;2021:1862446. doi: 10.1155/2021/1862446. eCollection 2021.
10
Management of Hepatitis B Virus Reactivation in Malignant Lymphoma Prior to Immunosuppressive Treatment.免疫抑制治疗前恶性淋巴瘤患者乙肝病毒再激活的管理
J Pers Med. 2021 Apr 2;11(4):267. doi: 10.3390/jpm11040267.